Galectin Therapeutics is a biopharmaceutical company that develops therapies for diseases including fibrotic and cancer. Its primary product candidate is belapectin, a substance in Phase III clinical trials for the treatment of diseases related to liver fibrosis as well as cancer. The company is also working on GM-CT-01, a pre-clinical substance for the treatment of cardiac and vascular fibrosis and additional applications for belapectin.